bioAffinity Technologies, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- bioAffinity Technologies, Inc. (NASDAQ: BIAF) develops noninvasive diagnostics for early-stage lung cancer and other lung diseases using flow cytometry and automated analysis; it also advances targeted cancer therapeutics through its subsidiary OncoSelect Therapeutics. The company offers CyPath Lung, a laboratory-developed test that analyzes sputum samples with a porphyrin molecule to detect cancer cells via fluorescence, marketed through its wholly owned subsidiary Precision Pathology Laboratory Services, LLC (PPLS) to high-risk patients following suspicious low-dose CT findings; additional pipeline efforts target diagnostics for other cancers and lung conditions like COPD via porphyrin-based flow cytometry, alongside broad-spectrum therapeutics that selectively kill cancer cells in preclinical stages. Founded in 2014 and headquartered in San Antonio, Texas, bioAffinity Technologies operates in the United States within the biotechnology and in vitro diagnostics industry, serving physicians, veterans' healthcare, and high-risk patient populations. In September 2023, the company acquired PPLS, boosting 2024 laboratory revenues toward $9.4 million with over 20% annualized growth and a 1,750% rise in CyPath Lung sales through November versus the prior year; recent achievements include securing reimbursement for CyPath Lung, gaining federal healthcare access, expanding the sales team, and streamlining operations ahead of national market rollout; bioAffinity closed a $4.8 million public offering in September 2025 via WallachBeth Capital to fund technology development.
Company News
BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
bioAffinity Technologies Announces Closing of $3.2 Million Offering
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
bioAffinity Technologies Announces Pricing of $3.2 Million Offering